There are over 200 medical cannabis products available in Germany, yet only 2 of them have market authorisation, why is that? Today's panel will be discussing why such few companies have pursued drug development and market authorisation. What role will approved finished drugs play in the future and what is the impact of legalisation of recreational cannabis? Will legislation affect the type of products available to patients? Our expert panel will provide their insights on the future of the German medical market.

Language: English

Speakers